News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

StemCells Inc. (STEM) Announces Completion Of The First Of Two Cohorts In Its Dry Age-Related Macular Degeneration Trial



2/12/2014 9:15:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SCĀ® product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was transplanted by Dr. Ted Leng, M.D. Director of Ophthalmic Diagnostics at the Byers Eye Institute at Stanford.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES